Financial StabilityCash runway is expected to fund operations into the second half of 2027, providing financial stability for ongoing projects.
Strategic DirectionThe strategic pivot focuses resources on siRNA for autoimmune disorders, showing a clear direction for future developments.
Technological AdvancementThe company has demonstrated success in delivering therapeutics into T-cells in animal studies, suggesting promising potential for future developments.